Agree we need P2 to maximise any deal and timeline is years off so patience is required. That’s what the Cosela (example) and Race trial timeframes / triangle report suggest.
P1 results will give insight into proof of concept for CPACS and thus a ‘major’ turning point in the development of RC220.
If you think P1 is ONLY a safety trial then think again. If CPACS isn’t present in P1 then I’m doubtful P2/P3
would show otherwise.
This is due to the way Cardio protection and FTO inhibition work.
Cardioprotection thread, page-436
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |